|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.09 USD | +4.76% |
|
+1.46% | -9.68% |
| 04:30am | BridgeBio Pharma, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02:20 PM | |
| 12/05 | BridgeBio Files New Drug Application for Rare Calcium Disorder Treatment | MT |
| Capitalization | 1.29TCr 1.1TCr 1.01TCr 955.53Cr 1.77TCr 1,23600Cr 1.78TCr 12TCr 4.69TCr 59TCr 4.85TCr 4.75TCr 2,03900Cr | P/E ratio 2026 * |
-30.2x | P/E ratio 2027 * | 132x |
|---|---|---|---|---|---|
| Enterprise value | 1.38TCr 1.18TCr 1.08TCr 1.02TCr 1.89TCr 1,32200Cr 1.9TCr 13TCr 5.01TCr 63TCr 5.18TCr 5.07TCr 2,18100Cr | EV / Sales 2026 * |
14.4x | EV / Sales 2027 * | 8.24x |
| Free-Float |
85.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BridgeBio Pharma, Inc.
| 1 day | +4.75% | ||
| 1 week | +1.46% | ||
| Current month | -2.85% | ||
| 1 month | -11.28% | ||
| 3 months | -8.19% | ||
| 6 months | +6.19% | ||
| Current year | -9.68% |
| 1 week | 63.88 |  | 70.24 |
| 1 month | 63.88 | | 84.75 |
| Current year | 62.77 | | 84.94 |
| 1 year | 31.77 | | 84.94 |
| 3 years | 12.75 | | 84.94 |
| 5 years | 4.98 | | 84.94 |
| 10 years | 4.98 | | 84.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Corporate Officer/Principal | 75 | 01/04/2019 | |
Neil Kumar
CEO | Chief Executive Officer | 47 | 01/04/2015 |
Charles Homcy
PRN | Corporate Officer/Principal | 77 | 01/02/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Charles Homcy
BRD | Director/Board Member | 77 | 01/11/2018 |
Eric Aguiar
BRD | Director/Board Member | 64 | 01/03/2019 |
James Momtazee
BRD | Director/Board Member | 54 | 01/03/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.76% | +1.46% | +107.71% | +365.53% | 1.29TCr | |
| -0.42% | -0.09% | +25.47% | -4.07% | 7.36TCr | |
| -0.91% | +3.51% | +50.99% | +180.50% | 5.39TCr | |
| -2.29% | +41.00% | +41.00% | +41.00% | 4.47TCr | |
| +0.24% | -20.59% | -57.99% | -67.75% | 3.45TCr | |
| +2.60% | +7.35% | +66.21% | -34.36% | 2.94TCr | |
| -5.17% | +3.29% | +97.70% | -61.31% | 2.11TCr | |
| -0.64% | -1.24% | +62.16% | +48.96% | 1.98TCr | |
| -1.86% | -5.38% | +76.21% | +118.99% | 1.97TCr | |
| -0.14% | -0.54% | +45.52% | +84.60% | 1.63TCr | |
| Average | -0.40% | -0.26% | +51.50% | +67.21% | 3.26TCr | |
| Weighted average by Cap. | -0.61% | -0.14% | +40.89% | +49.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 96Cr 82Cr 75Cr 71Cr 130.96Cr 9.15TCr 131.64Cr 890.77Cr 346.78Cr 4.34TCr 358.73Cr 351.21Cr 15TCr | 161.25Cr 137.71Cr 126.17Cr 119.28Cr 220.88Cr 15TCr 222.03Cr 1.5TCr 584.89Cr 7.32TCr 605.05Cr 592.36Cr 25TCr |
| Net income | -44Cr -37Cr -34Cr -32Cr -60Cr -4.18TCr -60Cr -406.45Cr -158.23Cr -1.98TCr -163.68Cr -160.25Cr -6.89TCr | 5.76Cr 4.92Cr 4.5Cr 4.26Cr 7.88Cr 550.9Cr 7.93Cr 54Cr 21Cr 261.43Cr 22Cr 21Cr 908.68Cr |
| Net Debt | 90Cr 77Cr 70Cr 66Cr 122.98Cr 8.59TCr 123.61Cr 836.47Cr 325.64Cr 4.08TCr 336.86Cr 329.8Cr 14TCr | 37Cr 32Cr 29Cr 27Cr 51Cr 3.55TCr 51Cr 345.79Cr 134.62Cr 1.69TCr 139.26Cr 136.34Cr 5.86TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | 69.09 $ | +4.76% | 24,08,935 |
| 12/26/12 | 65.95 $ | +1.96% | 24,10,010 |
| 11/26/11 | 64.68 $ | -4.02% | 36,48,394 |
| 08/26/08 | 67.39 $ | -0.09% | 54,01,590 |
| 07/26/07 | 67.45 $ | -0.94% | 28,75,634 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BBIO Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition